Halozyme Therapeutics reported $135K in Ordinary Share Capital for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
DBV Technologies DBVT:US USD 10.71M 1000
Agios Pharmaceuticals AGIO:US USD 71K 0
Alnylam Pharmaceuticals ALNY:US USD 1.23M 20K
Amarin AMRN:US USD 298.6M 3.94M
Amgen AMGN:US USD 32.37B 1.03B
Aptinyx Inc APTX:US USD 677K 0
Baxter International BAX:US USD 683M 0
Cara Therapeutics CARA:US USD 53K 0
Cytokinetics CYTK:US USD 93K 8K
Eli Lilly And LLY:US USD 594.1M 0
Esperion Therapeutics ESPR:US USD 72K 7K
Halozyme Therapeutics HALO:US USD 135K 3K
Immunogen IMGN:US USD 2.21M 2K
Intercept Pharmaceuticals ICPT:US USD 41K 11K
Intra Cellular Therapies ITCI:US USD 9K 0
IONIS PHARMACEUT IONS:US USD 142K 0
JAZZ PHA JAZZ:US USD 61K 0
Mannkind MNKD:US USD 2.63M 59K
Minerva Neurosciences NERV:US USD 1000 0
Nektar Therapeutics NKTR:US USD 19K 0
Peregrine Pharmaceuticals PPHM:US USD 62K 0
Rigel Pharmaceuticals RIGL:US USD 173K 0
United Therapeutics UTHR:US USD 700K 0
Vanda Pharmaceuticals VNDA:US USD 57K 0